BCAB

BioAtla, Inc.distress 8/10 · high distress / dilution risk

$3.30-3%today-95% from 52w high

bioatla.com41 employeesFounded 2007San Diego, CABiotechnology

Oncology 4

Lead: CAB-EpCAM x CAB-CD3 TCE · target PD-1

Revenue

pre-revenue

Liquidity

$2M

Runway

0.1 yrs

Shares 1y

+0%

Price & events

-79.4% over 6M

CatalystRating changeDilutionFinancingdashed = today

-2.7%

-17.3%

-7.6%

-36.0%

-81.3%

-83.5%

-96.2%

-99.8%

All

Overview

Market Cap: $106.64M
Volume: 1.85K
52 Week Range: $3.30 – $61.00
Total Shares: 32.32M
Float Shares: 1.37M
Short %: 9.46%
% Held by Insiders: 5.46%
% Held by Institutions: 22.50%
RVOL: 0.03x
Beta: 0.75

Pipeline stages · 4 programs

BA3182

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2028-09-15

Ozuriftamab Vedotin, Pembrolizumab, Evalstotug (BA3071)PD-1

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

CAB-AXL-ADC, PD-1 inhibitorPD-1

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

BA3071, Nivolumab, PembrolizumabPD-1

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

Pipeline · 5 trials · 1 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2028-09-15 Estimated 50% readout ~2028-10-15	Phase 1	BA3182	Advanced Adenocarcinoma	—	recruiting
2025-09-22	Phase 2	Ozuriftamab Vedotin, Pembrolizumab, Evalstotug (BA3071)	Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck	42	completed
2025-07-09	Phase 2	CAB-AXL-ADC, PD-1 inhibitor	Non-Small-Cell Lung Cancer	85	completed
2025-03-19	Phase 1/2	BA3071, Nivolumab, Pembrolizumab	NSCLC, Melanoma	320	active not recruiting
2025-01-08	Phase 1/2	CAB-AXL-ADC, PD-1 inhibitor	Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma	245	completed